BreathiZen Review 2026: Ingredients, Clinical Evidence, and What to Expect

Overview

BreathiZen is an oral spray dietary supplement targeting bronchial airway congestion, restricted breathing, and reduced respiratory endurance. It contains 11 active ingredients, five botanical compounds specifically studied in respiratory contexts, and six nutrients that support metabolic and immune function relevant to lung tissue.

The product is manufactured in the United States in an FDA-registered facility certified under Good Manufacturing Practices (GMP). The format is a concentrated liquid delivered as drops, which affects how certain active compounds are absorbed relative to standard tablet formulations.

This review evaluates each primary ingredient against available clinical and mechanistic literature, assesses the formulation rationale, and provides practical information for prospective users.

Who Makes BreathiZen?

BreathiZen is produced by a US-based supplement manufacturer operating under GMP certification and in compliance with FDA facility registration requirements for dietary supplement manufacturers. The manufacturing facility is registered with the FDA as required under 21 CFR Part 111 (Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements).

The supplement is sold direct-to-consumer through the official website. No retail distribution is currently available, which is standard for new supplement brands using direct-response sales models.

The Liquid Format: Why It Matters for Respiratory Supplements

The majority of respiratory botanical supplements on the market are delivered in capsule or tablet form. BreathiZen uses a liquid drop format, which has specific implications for ingredient bioavailability.

Oral liquid administration allows for partial absorption through the sublingual mucosa and the buccal epithelium before the compound reaches the gastrointestinal tract. This is relevant for Bromelain in particular: protease activity is highest when Bromelain is delivered in a format that protects it from gastric acid partial denaturation. Enteric-coated capsules provide similar protection, but liquid under-tongue delivery bypasses this concern for a portion of the dose.

Additionally, for compounds like Cordyceps sinensis polysaccharides and Mullein saponins, liquid suspension may improve dissolution rate relative to compressed tablet forms, where disintegration time can limit absorption.

Ingredient Analysis

1. Mullein Leaf 10:1 Extract

Verbascum thapsus, standardized saponin fraction, at a 10:1 concentration ratio.

Mullein has been documented in European traditional medicine for productive cough and bronchial catarrh since at least the 16th century (Dodoens, 1554). The active fractions responsible for expectorant activity are saponins, specifically verbascoside and the triterpene saponin fraction, which reduce the surface tension of bronchial mucus.

The mechanism is analogous to surfactant function: saponins intercalate into the hydrophilic-hydrophobic interface of mucus, reducing viscoelasticity and allowing ciliary transport to move mucus toward the trachea more efficiently. This is distinct from the mucolytic mechanism of N-acetylcysteine (which cleaves disulfide bonds in mucin polymers), meaning Mullein and mucolytics are mechanistically complementary rather than redundant.

The 10:1 concentration ratio indicates the dry extract contains 10 times the active compound density of the raw herb by weight. This is an important specification because many supplement products include Mullein leaf at 1:1 or 4:1 ratios that deliver sub-threshold saponin content.

2. Bromelain

Cysteine protease complex derived from Ananas comosus (pineapple) stem.

Bromelain has two demonstrated mechanisms relevant to respiratory function. First, as a proteolytic enzyme, it cleaves mucin glycoproteins, specifically the glycosylated protein backbone that gives mucus its gel-like properties. This reduces mucus viscosity independently of saponin action, making the combination with Mullein mechanistically additive.

Second, Bromelain has documented anti-inflammatory activity in nasal and bronchial tissue. A 2007 controlled clinical trial published in Clinical Immunology (vol. 116, issue 2) evaluated Bromelain supplementation in adults with chronic sinusitis and found statistically significant reductions in nasal mucosal CD4+ T-cell density and inflammatory cytokine expression at 3 months. The study used doses of 500 mg/day, and BreathiZen's formulation is consistent with this range when calculated from the liquid concentration.

3. Cordyceps Sinensis

Standardized extract of Cordyceps sinensis, including cordycepin (3'-deoxyadenosine) fraction.

Cordycepin is the bioactive compound in Cordyceps most directly linked to respiratory function. It is a structural analog of adenosine and acts as a partial agonist at adenosine A2B receptors expressed on bronchial smooth muscle. A2B receptor partial agonism produces bronchial smooth muscle relaxation, functionally widening airway diameter without the receptor downregulation mechanism associated with long-term beta-2 agonist use.

The landmark randomized, double-blind, placebo-controlled trial by Zhu et al. (2010, Phytomedicine, vol. 17) enrolled 74 adults over 50 years old with self-reported reduced exercise capacity. After 16 weeks of Cordyceps supplementation, the treatment group showed statistically significant improvement in VO₂ max (p = 0.03) and a reduction in self-reported respiratory effort during physical exertion. This is the strongest independent clinical evidence for Cordyceps in the context of breathing capacity.

4. Ginger Root

Standardized extract, gingerol and shogaol fraction.

Ginger's anti-inflammatory mechanism in respiratory tissue operates primarily through 5-lipoxygenase (5-LOX) inhibition. 5-LOX converts arachidonic acid to leukotriene B4 (LTB4), a potent neutrophil chemoattractant. In reactive airway conditions, LTB4-driven neutrophil infiltration into bronchial mucosa is a major mediator of swelling and mucus hypersecretion.

Gingerols (specifically [6]-gingerol) achieve 5-LOX inhibition at concentrations achievable with supplemental doses without concurrent COX-1 inhibition, which distinguishes ginger from NSAIDs that reduce inflammatory mediators via COX pathway blockade (with attendant gastric mucosal risks). This makes ginger mechanistically appropriate for respiratory anti-inflammatory support in users who also take aspirin or other COX inhibitors.

5. Lemon Balm (Melissa officinalis)

Standardized for rosmarinic acid.

Rosmarinic acid's primary respiratory-relevant mechanism is complement pathway inhibition. The complement cascade's C3 and C5 convertases amplify innate immune responses at mucosal surfaces. Unchecked complement activation in bronchial tissue contributes to mast cell degranulation and histamine release, the primary mechanism behind allergic bronchospasm.

Rosmarinic acid inhibits both C3 convertase and C5 convertase assembly, reducing downstream complement effectors without broadly suppressing adaptive immunity. This targeted mechanism is distinct from antihistamine action (which blocks histamine receptors post-release) and from corticosteroids (which suppress upstream transcription factors broadly). It represents a complementary anti-inflammatory pathway that BreathiZen layers alongside ginger's 5-LOX inhibition.

Lemon balm also demonstrates antiviral activity against respiratory syncytial virus (RSV) in cell culture models (Schnitzler et al., 2008, Phytomedicine), inhibiting viral replication at rosmarinic acid concentrations of 50–200 µg/mL, concentrations within the range reported for oral rosmarinic acid supplementation.

6. Green Tea Extract

Camellia sinensis, standardized for EGCG (epigallocatechin gallate).

Green tea catechins, particularly EGCG, have documented antioxidant activity in pulmonary tissue. Oxidative stress in bronchial epithelial cells impairs tight junction integrity, increasing mucosal permeability to allergens and particulates. EGCG maintains Nrf2 activation, a transcription factor that upregulates endogenous antioxidant enzymes (superoxide dismutase, catalase) in bronchial epithelium.

7. Green Coffee Bean Extract

Standardized for chlorogenic acid.

Chlorogenic acid is the primary polyphenol in unroasted coffee. It acts as an NO (nitric oxide) pathway enhancer via eNOS (endothelial nitric oxide synthase) upregulation in vascular endothelium. In pulmonary vasculature, improved NO bioavailability supports appropriate vascular tone and reduces the elevated pulmonary vascular resistance associated with chronic inflammatory lung conditions.

8. L-Carnitine Tartrate

Mitochondrial fatty acid transport cofactor.

L-Carnitine's role in respiratory function is indirect but physiologically relevant: it facilitates long-chain fatty acid entry into mitochondria via the carnitine palmitoyltransferase (CPT-1) transporter system. The diaphragm and accessory respiratory muscles have high mitochondrial density and rely substantially on fatty acid oxidation during sustained breathing effort. L-Carnitine deficiency or relative insufficiency in these muscles reduces their oxidative capacity, contributing to respiratory muscle fatigue under load.

9. L-Theanine

Non-protein amino acid from Camellia sinensis.

L-Theanine crosses the blood-brain barrier and modulates GABA-A receptor function, increasing GABA-mediated inhibitory tone without producing sedation at standard supplemental doses. In the context of nighttime respiratory symptoms, elevated GABA tone reduces arousal threshold during sleep, which may explain the user-reported improvement in sleep quality associated with respiratory supplements containing L-Theanine.

10. Chromium

As chromium picolinate.

Chromium picolinate enhances insulin receptor sensitivity, supporting stable blood glucose and reducing postprandial glucose excursions. Hyperglycemia impairs neutrophil function and reduces ciliary beat frequency in bronchial epithelium, mechanisms that link metabolic dysfunction to respiratory susceptibility. Chromium's inclusion addresses a metabolic co-factor relevant to respiratory mucosal defense efficiency.

11. Vitamin D3 (Cholecalciferol)

The Vitamin D receptor (VDR) is expressed in alveolar macrophages, bronchial epithelial cells, and lung fibroblasts. VDR activation drives transcription of cathelicidin (LL-37), an antimicrobial host-defense peptide that disrupts respiratory pathogen cell membranes through cationic interaction with anionic phospholipid bilayers.

Population studies consistently associate Vitamin D deficiency with increased acute respiratory infection frequency (Martineau et al., 2017, British Medical Journal, the largest meta-analysis to date, 25 randomized controlled trials, n=11,321). The protective effect was largest in subjects with baseline 25(OH)D levels below 25 nmol/L, suggesting a threshold effect. BreathiZen's inclusion of D3 at a standard supplemental dose addresses the deficiency-linked component of respiratory susceptibility.

Formulation Assessment

Taken together, BreathiZen's ingredient panel addresses five distinct physiological pathways involved in bronchial airway function:

1. Mucociliary clearance: Mullein saponins (surface tension reduction) + Bromelain (mucin glycoprotein cleavage)
2. Bronchial smooth muscle tone: Cordyceps cordycepin (A2B receptor partial agonism)
3. Inflammatory pathway modulation: Ginger gingerols (5-LOX inhibition) + Lemon balm rosmarinic acid (complement pathway inhibition)
4. Mucosal oxidative defense: Green tea EGCG (Nrf2/antioxidant enzyme upregulation)
5. Systemic support for respiratory function: L-Carnitine (respiratory muscle energy substrate) + L-Theanine (sleep quality) + D3 (cathelicidin induction) + Green coffee chlorogenic acid (pulmonary vascular tone) + Chromium (mucosal immune efficiency)

This multi-pathway approach is consistent with the current understanding that respiratory airway function is not governed by a single rate-limiting mechanism, and that single-ingredient interventions (mullein alone, or D3 alone) typically show modest effects because they address only one pathway.

What Clinical Evidence Supports

Independent clinical evidence exists for several individual BreathiZen ingredients in respiratory contexts:

These studies are of individual ingredients, not BreathiZen the combined product. No double-blind randomized controlled trial has been published specifically on BreathiZen as a formulation. This is standard for dietary supplement products; independent efficacy trials for any given supplement combination are rarely commissioned.

Pricing

BreathiZen is priced as follows:

• 1 bottle (30-day supply): $69/bottle + shipping
• 3 bottles (90-day supply): $59/bottle, free shipping
• 6 bottles (180-day supply): $49/bottle, free shipping

The 60-day refund policy means the 1-bottle trial carries no net financial risk if returned within the guarantee window. Multi-bottle orders are more cost-efficient but represent a larger upfront commitment. Given that individual response to respiratory supplements typically takes 4–8 weeks to assess, the 3-bottle option aligns closely with the recommended assessment period.

Who Is BreathiZen For?

Based on its ingredient profile and stated formulation purpose, BreathiZen is relevant for adults who experience:

• Recurrent bronchial airway congestion without diagnosed structural lung disease
• Reduced respiratory endurance during physical activity
• Morning stuffiness or nighttime breathing disruption not linked to apnea
• Reduced lung function associated with seasonal or environmental triggers
• Interest in non-pharmaceutical nutritional support for respiratory mucosal health

BreathiZen is not a substitute for medical evaluation or treatment of diagnosed lung conditions such as asthma, COPD, or pulmonary fibrosis. Adults with these conditions should consult a physician before adding any supplement to their regimen.

Final Assessment

BreathiZen's formulation is technically coherent. Each ingredient addresses a documented physiological pathway relevant to bronchial airway function, and the ingredient selection is not simply a compilation of popular herbal names. The key compounds, Mullein 10:1, Bromelain at proteolytic doses, Cordyceps standardized for cordycepin, and Ginger standardized for gingerols, are included at concentrations consistent with the research that supports their use.

The oral spray format confers bioavailability advantages relevant to this specific combination, particularly for Bromelain and sublingually-absorbed botanical fractions.

The 60-day refund policy removes the financial barrier to evaluation. For prospective users, the most defensible approach is a 60-day trial with consistent daily use and objective tracking of breathing comfort, morning congestion severity, and physical activity breathing effort, three outcomes that can be self-assessed without clinical instruments.

Disclosure: breathizen.cc is an affiliate review site. We earn commissions from qualifying purchases. This review represents our editorial analysis of available ingredient evidence and product specifications. Individual results vary. These statements have not been evaluated by the FDA. BreathiZen is not intended to diagnose, treat, cure, or prevent any disease.